GlassScriptPhysician profile
Zarmina Javed
NPI 1861001570
$2,054.56
in general payments reported to CMS, 2019-2025
26 companies · $753 in 2025
The $753 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.74 · 2022: $43.55 · 2023: $504 · 2024: $740 · 2025: $753.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,996.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,996.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $334.34 | 2023-2025 | |
| Biogen, INC. | $245.80 | 2024-2025 | Vumerity, Tysabri, Skyclarys |
| Takeda Pharmaceuticals U.S.A., INC. | $211.81 | 2023-2025 | Gammagard, Hyqvia |
| Merz Pharmaceuticals, LLC | $128.77 | 2023-2024 | Xeomin |
| Alexion Pharmaceuticals, INC. | $122.68 | 2023-2025 | Ultomiris, Soliris |
| Novartis Pharmaceuticals Corporation | $112.81 | 2025 | |
| Biocodex, INC. | $103.60 | 2023 | Diacomit |
| Genentech, INC. | $94.50 | 2024 | Ocrevus, Ocrevus Zunovo |
| Emd Serono, INC. | $85.38 | 2024-2025 | |
| Amgen INC. | $61.52 | 2025 | Uplizna |
| Genzyme Corporation | $58.94 | 2025 | |
| Argenx US, INC. | $55.76 | 2025 | Vyvgart Hytrulo |
| Medtronic, INC. | $54.83 | 2021-2024 | Linq II |
| Tg Therapeutics, INC. | $53.54 | 2025 | Briumvi |
| Jazz Pharmaceuticals INC. | $45.89 | 2022-2023 | Epidiolex |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $42.34 | 2024 | Xarelto |
| Neurocrine Biosciences, INC. | $34.54 | 2024 | Ingrezza |
| Neurelis, INC. | $34.41 | 2022-2023 | Valtoco |
| Genentech USA, INC. | $23.91 | 2025 | Ocrevus Zunovo |
| Catalyst Pharmaceuticals, INC. | $23.74 | 2024 | |
| Acadia Pharmaceuticals INC | $23.38 | 2024 | Nuplazid |
| Novo Nordisk INC | $21.18 | 2024 | |
| Eisai INC. | $21.05 | 2024 | |
| Immedica Pharma US, INC. | $20.52 | 2023 | |
| Lundbeck LLC | $20.13 | 2024 | Vyepti |
| Acorda Therapeutics, INC | $19.19 | 2024 | Inbrija |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zarmina Javed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.